Provided by Tiger Trade Technology Pte. Ltd.

crane

206.00
-2.4100-1.16%
Volume:248.59K
Turnover:51.58M
Market Cap:11.86B
PE:35.95
High:212.69
Open:210.64
Low:205.68
Close:208.41
52wk High:230.50
52wk Low:159.58
Shares:57.60M
Float Shares:48.76M
Volume Ratio:0.58
T/O Rate:0.51%
Dividend:0.98
Dividend Rate:0.48%
EPS(TTM):5.73
EPS(LYR):6.26
ROE:16.52%
ROA:12.73%
PB:5.45
PE(LYR):32.93

Loading ...

Crane Updates Financial Calendar with Second-quarter 2026 Earnings Release, Teleconference Schedule

Reuters
·
Jun 29

Crane Company Announces Date for Second Quarter 2026 Earnings Release and Teleconference

THOMSON REUTERS
·
Jun 29

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

GlobeNewswire
·
Jun 14

Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

GlobeNewswire
·
Jun 14

Honda Recalls Over One Million Vehicles in the U.S., Primarily Affecting CR-V and Accord Hybrid Models

Deep News
·
Jun 11

Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients

GlobeNewswire
·
Jun 11

Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026

GlobeNewswire
·
Jun 11

C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population

GlobeNewswire
·
Jun 11

Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress

GlobeNewswire
·
Jun 11

Crane NXT unit Antares Vision debuts laser spectroscopy leak detection tech at ProPak Asia

Reuters
·
Jun 09

ASCO 2026 | Updated Data from an Oral Presentation of InnoCare's Novel BCL2 Inhibitor Mesutoclax in MDS and AML Released

GlobeNewswire
·
Jun 03

Crane Is Maintained at Buy by DA Davidson

Dow Jones
·
Jun 02

Ascentage Pharma Presents Data on Olverembatinib in CML-LBP and Ph+ BCP-ALL at ASCO 2026

GlobeNewswire
·
Jun 01

Ascentage Pharma Presents Its First Dataset on MDM2-p53 Inhibitor Alrizomadlin (APG-115) in Pediatric Solid Tumors at ASCO 2026

GlobeNewswire
·
Jun 01

Moleculin Presents ASCO 2026 Data Demonstrating No Detectable Cardiotoxicity with Annamycin Despite Exposure Levels Far Exceeding Conventional Anthracycline Limits

GlobeNewswire
·
May 29

PeproMene Bio Announces Oral Presentation at EHA 2026 Highlighting Favorable Safety and Durable Responses with PMB-CT01 (BAFF-R CAR T-Cell Therapy) in B-cell Lymphomas, Including After Prior CD19 CAR T-Cell Failure

prnewswire
·
May 28

2026 ASCO | Pivotal Data of InnoCare's Novel BCL2 Inhibitor Mesutoclax Released

GlobeNewswire
·
May 22

Ascentage Pharma Releases Latest Clinical Data from Multiple Trials at ASCO 2026

GlobeNewswire
·
May 22

Moleculin Highlights Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting Highlighting Cardiac Safety Data for Annamycin

GlobeNewswire
·
May 22

Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC

GlobeNewswire
·
May 22